DNV GL and Renji Hospital have announced the renewal of their partnership, which has now entered its seventh year. This long-standing collaboration demonstrates their shared commitment to improving the quality of healthcare. In October 2020, VeChain (VET) joined forces with DNV GL, an independent assurance and risk management provider, to form a strategic partnership with Renji Hospital. Renji Hospital, affiliated with the Shanghai Jiao Tong University School of Medicine, is one of China’s largest hospitals. Together, they launched the world’s first Intelligent Tumor Treatment Center, powered by blockchain technology. This innovative treatment center, built on the VeChain Toolchain, aims to provide a transparent, efficient, and traceable medical management solution.
The partnership between DNV GL, Renji Hospital, and VeChain leverages the advantages offered by the VeChain blockchain and the professional services of DNV GL. The primary goal is to empower patients with control over their medical records. Additionally, authorized data can be utilized by both internal and external research institutions to enhance clinical research. Regulatory agencies can also conduct business compliance checks on medical institutions and evaluate their creditworthiness using this blockchain-enabled platform.
George Kang, Senior Vice President of DNV GL Group, expressed his thoughts on the partnership, stating that the Intelligent Tumor Treatment Center is intended to enhance the high-quality integrated development of Renji Hospital. He also mentioned that Renji Hospital plans to introduce more blockchain-powered use cases and projects to further enhance their healthcare facilities in collaboration with their partners.
Renji Hospital and DNV GL have now renewed their partnership for another year, further solidifying their relationship. This renewal is a testament to their shared commitment to improving international medical quality certification. Renji Hospital began the process of certifying its international outpatient program to DNV’s quality standards in January 2017. After passing the initial evaluation in April 2018, the hospital was able to enhance the quality of its services through this certification. The recent renewal demonstrates the ongoing dedication of both parties to continuously enhance international medical quality.
In line with the Chinese government’s 14th Five-Year Plan for Economic and Social Development, this initiative aligns with the guidelines set by the National Health Commission. The government recognizes blockchain technology as a crucial innovation for the medical and health industry. By utilizing the VeChain ToolChainTM, a self-developed one-stop data BaaS platform, VeChain has already implemented successful blockchain solutions in the medical sector. These include the blockchain-powered Clinical Trial Traceability Platform for Bayer China and the blockchain-enabled medical data management platform called The E-NewHealthLife for the Mediterranean Hospital of Cyprus. In response to the digital transformation demands brought about by the COVID-19 pandemic, VeChain, in partnership with DNV GL, aims to seize more opportunities to develop efficient and cost-effective digital solutions for the medical industry.
